|
Characteristics
|
All patients
|
High SUV
|
Low SUV
|
P -value b
|
|---|
|
Age at diagnosis, yr
| | | |
0.698
|
| |
Median (range)
|
48 (25 to 80)
|
48 (25 to 79)
|
49 (28 to 80)
|
|
Histology
| | | |
<0.001
|
| |
Invasive ductal carcinoma
|
416 (83.9)
|
173 (87.8)
|
243 (81.3)
| |
| |
Invasive lobular carcinoma
|
22 (4.4)
|
1 (0.5)
|
21 (7.0)
| |
| |
Mucinous carcinoma
|
13 (2.6)
|
2 (1.0)
|
11 (3.7)
| |
| |
Tubular carcinoma
|
6 (1.2)
|
0 (0.0)
|
6 (2.0)
| |
| |
Medullary carcinoma
|
4 (0.8)
|
4 (0.8)
|
0 (0.0)
| |
| |
Other invasive carcinoma
|
35 (7.7)
|
17 (8.6)
|
18 (6.0)
| |
|
T classification
| | | |
<0.001
|
| |
T1
|
270 (54.4)
|
68 (34.5)
|
202 (67.6)
| |
| |
T2
|
217 (43.8)
|
126 (64.0)
|
91 (30.4)
| |
| |
T3
|
9 (1.8)
|
3 (1.5)
|
6 (2.0)
| |
|
N classification
| | | |
0.016
|
| |
N0
|
329 (66.3)
|
115 (58.4)
|
214 (71.6)
| |
| |
N1
|
123 (24.8)
|
59 (29.9)
|
64 (21.4)
| |
| |
N2
|
30 (6.0)
|
17 (8.6)
|
13 (4.3)
| |
| |
N3
|
14 (2.8)
|
6 (3.0)
|
8 (2.7)
| |
|
AJCC stage
| | | |
<0.001
|
| |
I
|
200 (40.3)
|
42 (21.3)
|
158 (52.8)
| |
| |
II
|
252 (50.8)
|
131 (66.5)
|
121 (40.5)
| |
| |
III
|
44 (8.9)
|
24 (12.2)
|
20 (6.7)
| |
|
Histologic grade
c
| | | |
<0.001
|
| |
1
|
157 (35.0)
|
43 (22.8)
|
114 (44.0)
| |
| |
2
|
199 (44.4)
|
78 (41.3)
|
121 (46.7)
| |
| |
3
|
92 (20.5)
|
68 (36.0)
|
24 (9.3)
| |
|
ER
| | | |
0.001
|
| |
Positive
|
304 (61.3)
|
102 (51.8)
|
202 (67.6)
| |
| |
Negative
|
192 (38.7)
|
95 (48.2)
|
97 (32.4)
| |
|
PR
| | | |
0.005
|
| |
Positive
|
293 (59.1)
|
97 (49.2)
|
196 (65.6)
| |
| |
Negative
|
203 (40.9)
|
100 (50.8)
|
103 (34.4)
| |
|
HER-2
d
| | | |
<0.001
|
| |
Positive
|
127 (25.6)
|
72 (36.5)
|
55 (18.4)
| |
| |
Negative
|
369 (74.4)
|
125 (63.5)
|
244 (81.6)
| |
|
Ki67
| | | |
<0.001
|
| |
High
|
102 (20.6)
|
64 (32.5)
|
38 (12.7)
| |
| |
Low
|
394 (79.4)
|
133(67.5)
|
261 (87.3)
| |
|
Subtypes
| | | |
<0.001
|
| |
Luminal A
|
257 (51.8)
|
71 (36.0)
|
186 (62.2)
| |
| |
Luminal B
|
71 (14.4)
|
39 (19.8)
|
32 (10.7)
| |
| |
HER2
|
83 (16.7)
|
45 (22.8)
|
38 (12.7)
| |
| |
Triple negative
|
85 (17.1)
|
42 (21.3)
|
43 (14.4)
| |
|
Surgery type
| | | |
0.043
|
| |
Mastectomy
|
352 (70.9)
|
150 (76.1)
|
202 (67.5)
| |
| |
Breast-conserving surgery
|
144 (29.1)
|
47 (24.9)
|
97 (32.5)
| |
|
Adjuvant chemotherapy
| | | |
<0.001
|
| |
Yes
|
347 (70.0)
|
162 (82.2)
|
185 (61.9)
| |
| |
No
|
149 (30.0)
|
35 (17.8)
|
114 (38.1)
| |
|
Adjuvant endocrine therapy
| | | |
0.001
|
| |
Yes
|
332 (66.9)
|
114 (57.9)
|
218 (72.9)
| |
| |
No
|
164 (33.1)
|
83 (42.1)
|
81 (27.1)
| |
|
Adjuvant radiotherapy
| | | |
0.915
|
| |
Yes
|
189 (38.1)
|
74 (37.6)
|
115 (38.5)
| |
| |
No
|
307 (61.9)
|
123 (62.4)
|
184 (61.5)
| |
- aAJCC, American Joint Committee on Cancer; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; SUVmax, Maximum standardized uptake value. Data are number of patients (%), except for age. bχ2 test. cData with missing values. dHER2 positivity was defined as a 3+ score on immunohistochemistry or amplification on fluorescence in situ hybridization.
